CAR-T Meeting 2024 | The factors associated with poor outcomes following CAR-T in patients with myeloma
Luis-Esteban Tamariz-Amador
• 20 Feb 2024
Luis-Esteban Tamariz-Amador, MD, University Clinic of Navarra, Pamplona, Spain, outlines the factors associated with poor outcomes following CAR T-cell therapy in patients with multiple myeloma (MM), the two most relevant being the presence of extramedullary disease and high tumor burden. Dr Tamariz-Amador highlights that, in this setting, classification using the Revised International Staging System (RISS) holds greater clinical utility than information on high-risk cytogenetics. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
